EGFR target therapy is the standard first line treatment for lung cancer patients with EGFR mutations, and the data in Figure 4H showed that inhibition of EGFR activity by Gefitinib can block the effect of low-dose nicotine. The gene discussed is EGFR; the disease is lung carcinoma.